August 04, 2022
A proposed class of shareholders who sued a biopharmaceutical company over an unexpected delay in the approval of a breakthrough diabetes drug lost their case Thursday when a New Jersey federal judge said optimistic statements about the drug's future weren't actionable.
May 21, 2021
Biopharmaceutical company Provention Bio Inc. misled its shareholders about the pending approval of its type 1 diabetes drug and caused a stock drop of almost 18%, according to a proposed class action filed Friday in New Jersey federal court.